血脂检测临床应用的有关问题PPT.pptVIP

Related problems on clinical application of plasma lipids assay;All kinds of lipids in plasma were called blood lipids Total cholesterol，TC ＝free cholesterol＋cholesterol ester Neutral fatty—triglyceride，(TG) non esterified fatty acid （free fatty acid ，FFA） phospholipid , glucolipid Lipids were insoluble in water ,they were transported in the form of lipoprotein;Plasma lipoprotein;Clinical items for lipids detection;Cinical items for lipids analysis (2);The following factors may cause preanalytical variations;Behaviour factors (1) ; Behaviour factors (2) ;Smoking TG, LDL-C and Lp(a) ↑↑ apoA and HDL-C ↓↓ HDL-C ↓; Behaviour factors (4); Behaviour factors (5); Behaviour factors (6);Clinical factors therapeutic drugs (1);Immunosuppressive agents Codelcortone can increase the level of TC, LDL-C, HDL-C, TG, apoA and apoB. Ciclosporin can increase the level of TC, LDL-C, apoB，and decrease the level of Lp(a) . Tacrolimus —FK506 can decrease the level of TC. ; The division of abnormal lipids level; Risk rate; Medical decision level for lipid assay mmol/L(mg/dl);The classification of lipid level in ATP-III of the American National choleterol education project, mmol/L(mg/dl);Unit conversion for clinical routine of lipid items (primitive unit →legal unit);The application of clinical lipid assay;Clinical significance of lipid assay ( 1);Clinical significance of lipid assay ( 2);Diseases affecting the level of TC; Cinical significance of lipid assay (2); Hypertriglyceridemia; The level of the ApoA1 in fasting serum of normal cohort was about 1.20~1.60g/L. Generally speaking, the serum level of ApoA1 could represent the HDL. It was positively correlated to the level of the HDL-C. In CHD CVD patients, the ApoA1 was lower. In familial hypertriglyceridemia, the HDL-C was usually lower, but the level of the ApoA1 was uncertain and it did not increase the risk of CHD. However